Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6050076 | 0.94 | MTNR1A (0.49) | MTNR1AMTNR1BTAAR1L3MBTL1CYP1A2 | |
| SCHEMBL6667447 | 0.93 | AKR1C3 (0.50) | MTNR1AMTNR1BTAAR1CYP1A2HDAC1 | |
| SCHEMBL5077290 | 0.92 | MTNR1A (0.53) | MTNR1AMTNR1BHDAC1HDAC6 | |
| SCHEMBL10596068 | 0.90 | AKR1C3 (0.49) | MTNR1AMTNR1BTAAR1ABCB1HTR1A | |
| SCHEMBL11820853 | 0.88 | ABCB1 (0.51) | MTNR1AMTNR1BABCB1HTR1A | |
| SCHEMBL11815553 | 0.86 | MITF (0.54) | MTNR1AMTNR1BABCB1RAB9A | |
| SCHEMBL10202967 | 0.86 | MTNR1A (0.54) | MTNR1AMTNR1BTAAR1CYP1A2 | |
| SCHEMBL11419614 | 0.84 | MTNR1A (0.46) | MTNR1AMTNR1BCYP1A2 | |
| SCHEMBL30811394 | 0.84 | ALDH1A1 (0.56) | HDAC1RAB9A | |
| SCHEMBL9145931 | 0.84 | ALDH1A1 (0.56) | TAAR1L3MBTL1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256394-A1 | METHOD FOR THE PREPARATION OF LASOFOXIFENE | ZENTIVA K.S. (CZ) | 2010-10-07 | — | — | US | disclosed |
| US-20100256394-A1 | METHOD FOR THE PREPARATION OF LASOFOXIFENE | ZENTIVA K.S. (CZ) | 2010-10-07 | — | — | US | disclosed |
| WO-2008145075-A2 | METHOD FOR THE PREPARATION OF LASOFOXIFENE AND CRYSTALLINE INTERMEDIATES USED THEREIN | ZENTIVA, A.S. (CZ) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256394-A1 | METHOD FOR THE PREPARATION OF LASOFOXIFENE | SRD5A1, SRD5A2, CYP19A1 | MTNR1A 1695/4885MTNR1B 1678/4885TAAR1 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.